MX2024010110A - Tratamiento de la hipertrigliceridemia con 2-hidroxipropil-beta-ci clodextrina. - Google Patents

Tratamiento de la hipertrigliceridemia con 2-hidroxipropil-beta-ci clodextrina.

Info

Publication number
MX2024010110A
MX2024010110A MX2024010110A MX2024010110A MX2024010110A MX 2024010110 A MX2024010110 A MX 2024010110A MX 2024010110 A MX2024010110 A MX 2024010110A MX 2024010110 A MX2024010110 A MX 2024010110A MX 2024010110 A MX2024010110 A MX 2024010110A
Authority
MX
Mexico
Prior art keywords
hydroxypropyl
beta
hypertriglyceridemia
clodextrin
treatment
Prior art date
Application number
MX2024010110A
Other languages
English (en)
Spanish (es)
Inventor
Jason Camm
Original Assignee
Beren Therapeutics P B C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beren Therapeutics P B C filed Critical Beren Therapeutics P B C
Publication of MX2024010110A publication Critical patent/MX2024010110A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MX2024010110A 2022-02-18 2023-02-17 Tratamiento de la hipertrigliceridemia con 2-hidroxipropil-beta-ci clodextrina. MX2024010110A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263311536P 2022-02-18 2022-02-18
PCT/IB2023/051467 WO2023156970A1 (en) 2022-02-18 2023-02-17 Treatment of hypertriglyceridemia with 2-hydroxypropyl-beta-cyclodextrin

Publications (1)

Publication Number Publication Date
MX2024010110A true MX2024010110A (es) 2024-08-30

Family

ID=85476260

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024010110A MX2024010110A (es) 2022-02-18 2023-02-17 Tratamiento de la hipertrigliceridemia con 2-hidroxipropil-beta-ci clodextrina.

Country Status (11)

Country Link
US (1) US20240398849A1 (https=)
EP (1) EP4479064A1 (https=)
JP (1) JP2025508660A (https=)
KR (1) KR20240148426A (https=)
CN (1) CN118715017A (https=)
AU (1) AU2023222567A1 (https=)
CA (1) CA3244447A1 (https=)
IL (1) IL315046A (https=)
MX (1) MX2024010110A (https=)
TW (1) TW202342072A (https=)
WO (1) WO2023156970A1 (https=)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0307518A (pt) * 2002-02-01 2004-12-28 Shimoda Biotech Pty Ltd Composição farmacêutica
CN1745746A (zh) * 2004-09-09 2006-03-15 天津药物研究院 冰片的羟丙基－β－环糊精包合物及其制剂和制备方法
CN1961892A (zh) * 2005-11-08 2007-05-16 天津药物研究院 降香羟丙基－β－环糊精包合物及其制剂和制备方法
GB0710439D0 (en) * 2007-05-31 2007-07-11 Uni I Oslo Oral dosage form
JP5847721B2 (ja) * 2009-10-08 2016-01-27 ソン、ホ、バイオメッド、カンパニー、リミテッドＳｏｎｇ Ｈｏ Ｂｉｏｍｅｄ Ｃｏ．， Ｌｔｄ 高水溶性２−ヒドロキシプロピル−ベータシクロデキストリンを有効成分として含有する、肥満疾患の予防および治療用組成物
FR3014694B1 (fr) * 2013-12-13 2016-11-11 Roquette Freres Compositions a base de methyl-cyclodextrines pour le traitement et/ou la prevention de maladies par augmentation du taux de cholesterol-hdl

Also Published As

Publication number Publication date
IL315046A (en) 2024-10-01
WO2023156970A1 (en) 2023-08-24
JP2025508660A (ja) 2025-04-10
AU2023222567A1 (en) 2024-09-19
US20240398849A1 (en) 2024-12-05
KR20240148426A (ko) 2024-10-11
CA3244447A1 (en) 2023-08-24
EP4479064A1 (en) 2024-12-25
TW202342072A (zh) 2023-11-01
CN118715017A (zh) 2024-09-27

Similar Documents

Publication Publication Date Title
CR20220545A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
JOP20230284A1 (ar) سيكلو ألكيل ٣_ أوكسو بيبرازين كربوكساميدات وسيكلو هيترو ألكيل ٣_ أوكسو بيبرازين كربوكساميدات كمثبطات nav1.8
MX2022003193A (es) Tratamiento de encefalopatia asociada al gen syngap1.
AU2016202421B2 (en) Method of treating neurological conditions with cardiac glycosides
MX340441B (es) Proceso para tratar fibras queratinicas alaciadas.
WO2020058979A3 (en) Methods of treating amyotrophic lateral sclerosis
MX2021003006A (es) Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
AR075413A1 (es) Composiciones y metodo para usar aminopiridinas metodo para tratar la esclerosis multiple
EA201890859A1 (ru) Предотвращение, лечение и обращение развития заболевания с применением терапевтически эффективных количеств активированных жирных кислот
MX2022002418A (es) Composiciones y metodos de tratamiento de enfermedades vasculares.
MX2022000960A (es) Tratamiento de trastornos de la piel con composiciones topicas de tapinarof-inhibidor de egfr.
EA202193111A1 (ru) Композиции и способы для лечения рака
WO2022047128A3 (en) Method for treating complement mediated disorders caused by betacoronaviruses
EP4427738A3 (en) Dosing protocols and regimens for aminosterol treatment
MX2023012851A (es) Métodos de tratamiento y seguimiento de la enfermedad de parkinson.
MX2022014912A (es) Tratamiento del trastorno del espectro autista con cannabidiol.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
ECSP099308A (es) Métodos de tratamiento de la depresión
MX2024010110A (es) Tratamiento de la hipertrigliceridemia con 2-hidroxipropil-beta-ci clodextrina.
BG105163A (bg) Използване на аналог на валпроева киселина за лечение и профилактика на мигрена и афективни заболявания
AR122933A1 (es) Métodos para tratar la enfermedad cardiovascular
CL2022002104A1 (es) Tratamiento de infección por coronavirus con interferón lambda
WO2020005869A3 (en) Compositions and methods for the treatment of cancer characterized with pcsk9 expression
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
CL2021003303A1 (es) Tratamiento para sinucleinopatías.